NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--April 27, 2006--Senesco Technologies, Inc. (“Senesco” or the “Company”) (AMEX:SNT - News) announced today the results of a study conducted in Dr. John Thompson’s laboratory at the University of Waterloo in Ontario, Canada, in which mice injected with tumor-forming B16F0 melanoma cancer cells were treated with Senesco’s proprietary gene, eIF-5A (“Factor 5A”). Tumors of adequate size formed in approximately nine days at which time treatment was initiated. Two control groups of nine mice each received placebo treatments and a test group of ten mice received Factor 5A, intratumorally, every other day. The median survival of the control mice was 7 days post-treatment, whereas, the mice that received Factor 5A treatment had a median survival of 25 days post-treatment (P less than 0.001). The enhanced survival time of the Factor 5A-treated mice equates to 3.5 fold or a 250% increase compared to the control mice. Two of the Factor 5A-treated mice are still alive, with one mouse in apparent complete remission. None of the control mice survived.
